Ignite Creation Date:
2024-07-17 @ 10:42 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06491472
Status:
RECRUITING
Last Update Posted:
2024-07-09
First Post:
2024-06-27
Brief Title:
IvonescimabAK112SMT112 in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
Sponsor:
Wuhan Union Hospital China
Organization:
Wuhan Union Hospital China
Study Overview
Official Title:
Efficacy and Safety of IvonescimabAK112SMT112 in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic CancerA Single-arm Open-label Phase II Clinical Study
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is an open-label single-arm Phase II clinical study to evaluate the efficacy and safety of ivonescimabAK112SMT112 in combination with stereotactic body radiation therapy and chemotherapy in patients with pancreatic cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None